Enlight Renewable Energy stock rises after major German energy storage investment

Investing.com – France stocks were higher after the close on Monday, as gains in the Consumer Services, Basic Materials and Financials sectors led shares higher.

At the close in Paris, the CAC 40 rose 0.67%, while the SBF 120 index added 0.65%.

The best performers of the session on the CAC 40 were Danone SA (EPA:DANO), which rose 4.74% or 3.12 points to trade at 68.96 at the close. Meanwhile, ArcelorMittal SA (AS:MT) added 3.94% or 1.81 points to end at 47.79 and Accor SA (EPA:ACCP) was up 3.23% or 1.48 points to 47.34 in late trade.

The worst performers of the session were Kering SA (EPA:PRTP), which fell 2.12% or 5.60 points to trade at 258.55 at the close. LVMH Moet Hennessy Louis Vuitton SE (EPA:LVMH) declined 1.57% or 8.60 points to end at 538.30 and TotalEnergies SE (EPA:TTEF) was down 0.85% or 0.52 points to 60.63.

The top performers on the SBF 120 were Atos SE (EPA:ATOS) which rose 5.13% to 58.20, Danone SA (EPA:DANO) which was up 4.74% to settle at 68.96 and Air France KLM SA (EPA:AIRF) which gained 4.67% to close at 11.32.

The worst performers were Eramet SA (EPA:ERMT) which was down 9.69% to 66.65 in late trade, Worldline SA (EPA:WLN) which lost 5.01% to settle at 1.36 and SES (EPA:SESFd) which was down 3.47% to 6.68 at the close.

Rising stocks outnumbered declining ones on the Paris Stock Exchange by 270 to 223 and 82 ended unchanged.

Shares in ArcelorMittal SA (AS:MT) rose to 5-year highs; gaining 3.94% or 1.81 to 47.79.

The CAC 40 VIX, which measures the implied volatility of CAC 40 options, was unchanged 0.00% to 18.96 a new 52-week high.

Gold Futures for April delivery was down 1.01% or 47.84 to $4,697.26 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in March fell 5.09% or 3.32 to hit $61.89 a barrel, while the April Brent oil contract fell 4.70% or 3.26 to trade at $66.06 a barrel.

EUR/USD was unchanged 0.35% to 1.18, while EUR/GBP unchanged 0.12% to 0.86.

The US Dollar Index Futures was up 0.55% at 97.39.

Investing.com – Belgium stocks were higher after the close on Monday, as gains in the Consumer Goods, Financials and Healthcare sectors led shares higher.

At the close in Brussels, the BEL 20 rose 1.37% to hit a new all time high.

The best performers of the session on the BEL 20 were KBC Groep NV (EBR:KBC), which rose 2.90% or 3.45 points to trade at 122.35 at the close. Meanwhile, Syensqo SA (EBR:SYENS) added 2.79% or 1.98 points to end at 73.00 and D’Ieteren NV (EBR:IETB) was up 2.44% or 4.70 points to 197.60 in late trade.

The worst performers of the session were Umicore SA (EBR:UMI), which fell 2.89% or 0.58 points to trade at 19.52 at the close. Azelis Corporate Services NV (EBR:AZE) declined 0.90% or 0.08 points to end at 8.29 and Sofina (EBR:SOF) was down 0.81% or 2.00 points to 244.00.

Rising stocks outnumbered declining ones on the Brussels Stock Exchange by 53 to 41 and 14 ended unchanged.

Shares in KBC Groep NV (EBR:KBC) rose to all time highs; gaining 2.90% or 3.45 to 122.35. Shares in D’Ieteren NV (EBR:IETB) rose to 52-week highs; rising 2.44% or 4.70 to 197.60.

Gold Futures for April delivery was down 1.10% or 52.36 to $4,692.74 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in March fell 5.18% or 3.38 to hit $61.83 a barrel, while the April Brent oil contract fell 4.80% or 3.33 to trade at $65.99 a barrel.

EUR/USD was unchanged 0.34% to 1.18, while EUR/GBP unchanged 0.12% to 0.86.

The US Dollar Index Futures was up 0.54% at 97.38.

Investing.com - Futures linked to Canada’s commodities-heavy main stock index were subdued on Monday, as analysts gauged a slide in gold and silver prices.

By 07:03 ET (12:03 GMT), the S&P/TSX 60 index standard futures contract was mostly unchanged.

On Friday, the S&P/TSX composite index slumped by 3.3% to 31,923.52, marking the worst one-day fall for the index since last April. At that time, the prospect of sweeping U.S. tariffs was weighing on the average.

The slip brought the first trading month of the year to a downbeat close. Still, for January as a whole, the index notched a 0.7% gain, a ninth straight monthly climb.

Beyond metals, shares of Bombardier retreated after U.S. President Donald Trump threatened to decertify its business jets and slap a 50% tariff on Canadian-made aircraft unless regulators in Ottawa certify planes made by American group Gulfstream.

U.S. futures drop

U.S. stock futures fell as sharp falls in gold and silver prices hit investor sentiment ahead of a packed week of corporate earnings and economic data.

At 07:19 ET, Dow Jones Futures traded 23 points, or 0.1%, lower, S&P 500 Futures dropped 25 points, or 0.4%, and Nasdaq 100 Futures declined 170 points, or 0.7%.

The major benchmarks suffered a losing session at the end of last week after the nomination by President Donald Trump of Kevin Warsh as his pick for Federal Reserve chairman. If confirmed, Warsh would replace Jerome Powell in May.

Gold, silver selloff hits sentiment

Sentiment has been hard hit by a steep decline in gold and silver prices, extending Friday’s historic tumble, with the precious metals hit by a combination of a firmer dollar and mass profit-taking in the wake of a sharp climb in recent months.

After a nearly 10% drop late last week, spot gold has fallen another 1.8%, slipping well below a $5,000 level it had topped only days ago. Silver, until recently a beneficiary of speculative investments and burnished by its practical applications in a range of industries, was also under pressure, after last Friday’s 30% slump that saw the metal log its worst day in decades.

The nomination of Kevin Warsh as the next Fed chair also weighed heavily as it resulted in a sharp rise in the U.S. dollar. While Warsh -- who formerly served as a Fed governor -- has aligned with Trump’s calls for sharply lower interest rates, he has also balked at the Fed’s asset buying operations.

"The main macro topic of debate remains the Fed balance sheet, and the potential for Warsh to either shrink it outright or dramatically alter the composition of its assets (by aggressively shifting the duration toward the short-end of the curve), a move that could tighten financial conditions even if the Funds Rate is slashed," said analysts at Vital Knowledge, in a note.

Economic data later in the week could further influence rate expectations. The keenly-watched U.S. January employment report, due on Friday, is expected to show steady job growth and a stable unemployment rate.

Walt Disney leads earnings parade

The quarterly earnings season is set to continue in full flow this week.

Prior to the opening bell, Walt Disney posted better-than-expected fiscal first-quarter income thanks to ongoing strength at its theme parks business, although a dispute with YouTube weighed on earnings during the quarter.

More than 100 S&P 500 companies are due to report this week, including tech giants Amazon and Alphabet.

Microsoft’s earnings update last week, which, while showing continued revenue growth, failed to fully reassure markets about the near-term payoff from heavy investment in AI infrastructure.

Amplifying concerns, a Wall Street Journal report over the weekend said that Nvidia’s proposed investment of up to $100 billion in OpenAI has stalled after internal concerns were raised at the chipmaker.

Elsewhere, Oracle on Sunday outlined its plans to raise fresh funds in 2026 that it will deploy towards building out its AI and cloud infrastructure, amid growing demand for more computing capacity.

The company said it expects to raise between $45 billion and $50 billion of gross cash proceeds in 2026, through a mix of debt and equity financing.

Crude falls as Iran risks recede

Oil prices fell sharply Monday as concerns of a U.S. strike on Iran eased, after President Trump said the Middle East crude producer was "seriously talking" with Washington.

Brent futures dropped 4.4% to $66.26 a barrel and U.S. West Texas Intermediate crude futures fell 4.6% to $62.19 a barrel.

Crude prices had risen sharply last week as markets priced in a greater risk of supply disruptions from this key region after Trump had repeatedly threatened Iran with military action over a nuclear deal and ongoing protests in the country.

However, risks of a military strike receded after Trump’s weekend comments.

The Organization of Petroleum Exporting Countries and allies, a group known as OPEC+, left production unchanged during a weekend meeting, as broadly expected.

Investing.com – Sweden stocks were higher after the close on Monday, as gains in the Healthcare, Telecoms and Financials sectors led shares higher.

At the close in Stockholm, the OMX Stockholm 30 gained 1.33% to hit a new all time high.

The best performers of the session on the OMX Stockholm 30 were AstraZeneca PLC (ST:AZN), which rose 4.03% or 66.50 points to trade at 1,716.00 at the close. Meanwhile, Nordea Bank Abp (ST:NDASE) added 3.20% or 5.50 points to end at 177.40 and Skandinaviska Enskilda Banken AB A (ST:SEBa) was up 2.51% or 4.80 points to 196.15 in late trade.

The worst performers of the session were SAAB AB ser. B (ST:SAABb), which fell 2.39% or 16.60 points to trade at 676.70 at the close. Evolution AB (ST:EVOG) declined 1.66% or 9.60 points to end at 569.00 and H & M Hennes & Mauritz AB B (ST:HMb) was down 0.87% or 1.60 points to 176.80.

Falling stocks outnumbered advancing ones on the Stockholm Stock Exchange by 397 to 364 and 60 ended unchanged.

Shares in Evolution AB (ST:EVOG) fell to 5-year lows; down 1.66% or 9.60 to 569.00.

Crude oil for March delivery was down 5.06% or 3.30 to $61.91 a barrel. Elsewhere in commodities trading, Brent oil for delivery in April fell 4.67% or 3.24 to hit $66.08 a barrel, while the April Gold Futures contract fell 1.25% or 59.24 to trade at $4,685.86 a troy ounce.

EUR/SEK was up 0.17% to 10.58, while USD/SEK rose 0.51% to 8.96.

The US Dollar Index Futures was up 0.55% at 97.39.

Investing.com -- Sagimet Biosciences Inc (NASDAQ:SGMT) stock rose 4.6% Monday following positive topline results from a long-term safety study of denifanstat in acne patients conducted by its Chinese partner Ascletis Pharma.

The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in China and by Sagimet for MASH (Metabolic dysfunction-Associated SteatoHepatitis) in the rest of the world.

The study showed denifanstat was generally well tolerated, with only two categories of treatment-emergent adverse events occurring in more than 5% of patients: dry eye syndrome (5.5%) and dry skin (5.2%). All drug-related adverse events were mild or moderate, with no permanent discontinuations due to adverse events.

"The topline results from Ascletis’ Phase 3 open-label acne trial in China build additional confidence in the clinical potential of FASN inhibition in acne," said David Happel, Chief Executive Officer of Sagimet. "These results demonstrate FASN inhibition’s potential as a novel mechanism of action for the treatment of acne."

This follows Ascletis’ announcement in June that denifanstat met all primary, key secondary, and secondary endpoints in a 480-patient randomized, double-blind, placebo-controlled Phase 3 clinical trial for moderate to severe acne.

Patients in the open-label extension who were originally randomized to denifanstat in the previous trial had a total of 52 weeks of exposure to the drug, providing valuable long-term safety data for the once-daily oral fatty acid synthase inhibitor.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.